Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
samatasvir + simeprevir
- Development stage
- Unknown
- Lead developer
- Medivir
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Samatasvir + simeprevir is an investigational oral combination regimen evaluated for the treatment of chronic hepatitis C virus (HCV) infection. Samatasvir (IDX719) is an NS5A inhibitor, and simeprevir (TMC435) is an NS3/4A protease inhibitor. Both drugs interrupt the viral lifecycle at distinct stages: samatasvir by inhibiting the NS5A protein needed for viral replication and assembly, and simeprevir by inhibiting the NS3/4A protease required for HCV polyprotein processing. The combination aims for synergistic antiviral activity against HCV genotypes 1b, 4, and 6. This regimen was tested in phase II/III trials, usually as part of a 12-week all-oral regimen, often alongside ribavirin or other antivirals, in treatment-naïve and treatment-experienced (interferon/ribavirin-relapsed) patients[1][3][5].
- Other names
- samatasvir + simeprevir
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on samatasvir + simeprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on samatasvir + simeprevir.